Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ymgme.2016.09.003PMID 27692945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mucopolysaccharidosis enzyme production by bone marrow and dental pulp derived human mesenchymal stem cells.

  2015cited by this paper
• Lentiviral-Mediated Gene Therapy Results in Sustained Expression of β-Glucuronidase for up to 12 Months in the Gus mps/mps and up to 18 Months in the Gus tm(L175F)Sly Mouse Models of Mucopolysaccharidosis Type VII

  2014cited by this paper
• Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII

  2013cited by this paper
• The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.

  2013cited by this paper
• Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII.

  2012cited by this paper
• Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.

  2012cited by this paper
• Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII.

  2010cited by this paper
• Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.

  2009cited by this paper
• Musculoskeletal manifestations of lysosomal storage disorders

  2009cited by this paper
• Mechanism of shortened bones in mucopolysaccharidosis VII.

  2009cited by this paper
• Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues.

  2009cited by this paper
• Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

  2008cited by this paper
• Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.

  2008cited by this paper
• Musculoskeletal complications encountered in the lysosomal storage disorders.

  2008cited by this paper
• Functions of RANKL/RANK/OPG in bone modeling and remodeling.

  2008cited by this paper
• Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation

  2008cited by this paper
• A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

  2007cited by this paper
• Inhibition of Glycosaminoglycan Synthesis Using Rhodamine B in a Mouse Model of Mucopolysaccharidosis Type IIIA

  2006cited by this paper
• Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

  2006cited by this paper
• Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin

  2003cited by this paper
• Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-β by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts*

  2003cited by this paper
• Stem cell bone marrow transplantation in patients with metabolic storage diseases.

  2002cited by this paper
• Histochemical Localization of Alkaline Phosphatase Activity in Decalcified Bone and Cartilage

  2002cited by this paper
• Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease.

  2002cited by this paper
• Receptor Activator for Nuclear Factor Kappab Ligand and Osteoprotegerin: Regulators of Bone Physiology and Immune Responses/Potential Therapeutic Agents and Biochemical Markers

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer

  2001cited by this paper
• Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

  1999cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function.

  1997cited by this paper
• Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

  1997cited by this paper
• Gene therapy for murine mucopolysaccharidosis type VII.

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses.

  1997cited by this paper
• Clinical and biochemical manifestations of hyaluronidase deficiency.

  1996cited by this paper
• Modulation of osteoclast differentiation by local factors.

  1995cited by this paper
• The biology and action of colony stimulating factor-1.

  1994cited by this paper
• The biology and action of colony stimulating factor-1.

  1994cited by this paper
• Correction of Murine Mucopolysaccharidosis Type VII (MPS VII) by Bone Marrow Transplantation and Gene Transfer Therapy

  1991cited by this paper
• Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.

  1989cited by this paper
• PERIODATE-LYSINE-PARAFORMALDEHYDE FIXATIVE A NEW FIXATIVE FOR IMMUNOELECTRON MICROSCOPY

  1974cited by this paper
• New method for quantitative determination of uronic acids.

  1973cited by this paper
• Complexes of organic acids with calcium phosphate: the von Kossa stain as a clue to the composition of bone mineral.

  1971cited by this paper

• In vivo direct lentiviral gene therapy improves disease pathology in a mucopolysaccharidosis IVA murine model

  2025cites this paper
• Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model

  2024cites this paper
• Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)

  2022cites this paper
• Gene editing strategies to treat lysosomal disorders: the example of mucopolysaccharidoses.

  2022cites this paper
• Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases

  2021cites this paper
• Mucopolysaccharidosis type VII presenting as neonatal cholestasis

  2020cites this paper
• Failures of Endochondral Ossification in the Mucopolysaccharidoses

  2020cites this paper
• C-type natriuretic peptide restores growth impairment under enzyme replacement in mice with mucopolysaccharidosis VII.

  2020cites this paper
• Hurdles in treating Hurler disease: potential routes to achieve a "real" cure.

  2020cites this paper
• Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.

  2020cites this paper
• Altered IHH signaling contributes to reduced chondrocyte proliferation in the growth plate of MPS VII mice

  2020cites this paper
• Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases

  2019cites this paper
• Delayed development of ossification centers in the tibia of prenatal and early postnatal MPS VII mice.

  2018cites this paper
• Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice

  2017cites this paper
• Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome)

  2017cites this paper